TIL Therapy for Metastatic Renal Cell Carcinoma
T Cell Therapy for Patients With Metastatic Renal Cell Carcinoma
Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has achieved impressive clinical results with durable complete responses in patients with metastatic melanoma. The TILs are isolated from patients own tumor tissue followed by in vitro expansion and activation for around 4-6 weeks. Before TIL infusion the patients receive 1 week of preconditioning chemotherapy with cyclophosphamide and fludarabine. After TIL infusion Interleukin-2 is administered to support T cell activation and proliferation in vivo.
Recent studies suggest, that TIL therapy works in other cancers than Metastatic Melanoma, including Renal Cell Carcinoma. In this study TIL therapy is administered to patients with metastatic Renal Cell Carcinoma.
Study Overview
Status
Conditions
Detailed Description
Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has achieved impressive clinical results with durable complete responses in patients with metastatic melanoma. The TILs are isolated from patients own tumor tissue followed by in vitro expansion and activation for around 4-6 weeks. Before TIL infusion the patients receive 1 week of preconditioning chemotherapy with cyclophosphamide and fludarabine. After TIL infusion Interleukin-2 is administered to support T cell activation and proliferation in vivo.
Objectives:
To evaluate safety and feasibility when treating patients with metastatic renal cell carcinoma with ACT with TILs.
To evaluate treatment related immune responses . To evaluate clinical efficacy.
Design:
Patients will be screened with a physical exam, medical history, blood samples, pulmonary function test, Cr-EDTA clearance, MUGA scan and ECG.
Patients will undergo surgery to harvest tumor material for TIL production.
Patients is admitted day -8 in order to undergo lymphodepleting chemotherapy with cyclophosphamide and fludara starting day -7.
On day 0 patients receive TIL infusion and shortly after starts IL-2 administration with high-dose bolus IL-2 every eight hour for up to 5 days (maximum of 15 doses).
The patients will followed until progression or up to 5 years.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Herlev, Denmark, 2730
- Center for Cancer Immune Therapy Dept. of Hematology/oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histological proven mRCC with the possibility of surgical removal of tumor tissue of > 1 cm3. Histology must include a clear cell component with or without a sarcomatoid dedifferentiation.
- Metastatic disease irrespective of number of previous treatment lines. Treatment naïve pt's can be included.
- ECOG performance status of ≤1.
- IMDC prognostic group 'Favorable' or 'Intermediary'.
- Life expectancy of > 6 months.
- At least one measurable parameter after surgery in accordance with RECIST 1.1 -criteria's.
- No significant toxicities or side effects (CTC ≤ 1) from previous treatments.
- Normal ejection fraction (EF) measured by a multigated acquisition (MUGA) scan.
- Crom EDTA clearance >40 ml/min.
- Adequate renal, hepatic and hematological function.
- LDH ≤ 5 times upper normal limit as a measure of tumor burden.
- Women in the fertile age must use effective contraception. Likewise, men included in the study, as well as their partners, must use effective contraception. This applies from inclusion and until 6 months after treatment. Birth control pills, spiral, depot injection with gestagen, subdermal implantation, hormonal vaginal ring and transdermal depot patch are all considered safe contraceptives.
- Able to comprehend the information given and willing to sign informed consent.
- Willingness to participate in the planned controls.
Exclusion Criteria:
- A history of prior malignancies, except curatively treated non-melanoma skin cancer and CIS of the cervix uteri. Patients treated for another malignancy can participate if they are without signs of disease for a minimum of 3 years after treatment.
- Patients with cerebral metastases.
- Patients with widespread bone or bone only metastases.
- Severe allergies, history of anaphylaxis or known allergies to the administered drugs.
- Severe medical conditions or psychiatric comorbidity.
- Acute/chronic infection with HIV, hepatitis, tuberculosis among others.
- Severe and active autoimmune disease.
- Pregnant women and women breastfeeding.
- Simultaneous treatment with systemic immunosuppressive drugs (including prednisolone, methotrexate among others).
- Simultaneous treatment with other experimental drugs.
- Simultaneous treatment with other systemic anti-cancer treatments.
- Patients with active and uncontrollable hypercalcaemia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Patient group
All patients receive the same treatment. Surgical removal of tumor tissue for T cell production, which takes 4-6 weeks, is performed initially. All patients are hospitalized during treatment (one week in advance of the T cell product being ready and for approximately 3 weeks in total) and receive treatment only once. The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine on day -7 to day -1. The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 5. Interleukin-2 is administered as high-dose i.v. bolus every eight hour starting approximately 6 hours after TIL infusion and for up to 5 days (maximum of 15 doses). |
Surgical removal of > 1 cm3 tumor tissue chosen with regards to high rate of success and to minimize the general risks involved in a surgical procedure.
Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
Other Names:
Fludarabine 25 mg/m2 is administered on day -5 to day -1.
Maximum dose of 50 mg per administration.
Other Names:
The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
Other Names:
Interleukin-2 is administered as high-dose bolus infusions (600.000
IU/kg) over a 15 minute period every 8 hours and continuing for up to 5 days (maximum of 15 doses).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Patients in Which the Treatment Was Tolerable
Time Frame: 0-24 weeks
|
Determine the safety of the administration of TIL therapy including lymphodepleting chemotherapy and Interleukin-2 for patients with metastatic renal cell cancer.
This will be assessed clinically by whether the patients are able to receive treatment as described in the protocol.
|
0-24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Infusion Products With Detectable in Vitro Anti-tumor Responses
Time Frame: Up to 12 months
|
In vitro anti-tumor responses will be measured by cytokine production in a flow-cytometry based assed after co-culture of tumor-infiltrating lymphocytes from the infusion product with autologous tumor cells (from tumor digest and/or autologous tumor cell lines).
|
Up to 12 months
|
|
Objective Response Rate
Time Frame: Up to 12 months
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
|
Up to 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Inge M Svane, Prof., MD, Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital, Borgmester Ib Juuls vej 25C, DK-2730
- Principal Investigator: Troels H Borch, MD, PhD, Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital, Borgmester Ib Juuls vej 25C, DK-2730
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Urologic Neoplasms
- Kidney Neoplasms
- Carcinoma
- Carcinoma, Renal Cell
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Antirheumatic Agents
- Sensory System Agents
- Analgesics, Non-Narcotic
- Analgesics
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
- Interleukin-2
Other Study ID Numbers
- UG1617
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.